SABCS 2021
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
SABCS 2021
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
News
This study raises important questions about the choice between lactated Ringer and saline.
News
A study found no significant increased risks for death or major adverse cardiac events among infected patients with established chronic kidney disease or end-stage kidney disease.
News
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
News
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
News
Study findings highlight an "unmet need" for newer therapies.
